comprehensive -WSS

comprehensive

author：leisure time 2025-10-02 18:49:49 - browse：696

A person picking up medication at a drive through pharmacy window – biotech and pharma coverage from STAT — Adobe

On Tuesday morning, the Department of Health and Human Services unveiled its long-awaited list of the 10 medicines that will be subject to price negotiation in 2026 under the Inflation Reduction Act.

This will mark the first time that Medicare, the government program for paying for health care for older Americans, will have any ability to use its vast size to negotiate for lower prices. It’s not yet clear how big the discounts on these 10 drugs will be, or even if the law will hold up to multiple legal challenges from the pharmaceutical industry. It’s also not clear, as critics from the drug industry have noted, whether any savings to the government will be passed on to consumers.

Still, the naming of 10 medicines is a milestone, and a point to start appraising the impact of the law. The landscape here is complicated. No one really knows how the IRA’s price negotiation process will play out over the short and long term, and many companies who had products named were spared in other ways, with products many industry watchers expected to see on the list absent. Here is STAT’s assessment of who has won and lost.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Lung cancer screening guidelines updated for cigarette smokers

hotspot

explore

WSS

Key Senate panel to consider PBM, drug pricing reform package

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

Travis Kelce and the trap of celebrity vaccine endorsements

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

Medicare must police algorithms in Medicare Advantage, Dems say

Some top drug companies are starting to take action on climate

knowledge

comprehensive

knowledge

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Experts study whether long Covid risk adds up with each reinfection

Drug repurposing or repositioning? The language matters

CRISPR base editing slashes cholesterol levels in monkeys

23andMe had bad news about my health. I wish a person had delivered it

DeepMind touts AlphaFold's new skills as protein folding AI models face off

State Dept. review finds Biden bears some blame for Afghanistan failures

CRISPR base editing slashes cholesterol levels in monkeys

Cancer drug shortages should be causing more outrage

Brain injuries and the importance of a second opinion

focus

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

Key Senate panel to consider PBM, drug pricing reform package

Explaining an after

All of Us, NIH's precision medicine initiative, gets a big boost

What is microchimerism and how does it affect maternal health?

What will Novo Nordisk's VC do with its influx of cash?

hotspot

explore

explore

leisure time